Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis.
Journal
Cell stem cell
ISSN: 1875-9777
Titre abrégé: Cell Stem Cell
Pays: United States
ID NLM: 101311472
Informations de publication
Date de publication:
07 05 2020
07 05 2020
Historique:
entrez:
11
5
2020
pubmed:
11
5
2020
medline:
24
4
2021
Statut:
ppublish
Résumé
Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making the transition from laboratory to clinical trials. While animal models provide the experimental flexibility to analyze mechanisms of remyelination, here we discuss the challenges in understanding where and how remyelination occurs in MS.
Identifiants
pubmed: 32386552
pii: S1934-5909(20)30139-9
doi: 10.1016/j.stem.2020.03.017
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
617-619Subventions
Organisme : Medical Research Council
ID : G0701476
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_12009
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17230
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203151/Z/16/Z
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declarations of Interest R.J.M.F. is a scientific advisory board member of Frequency Therapeutics, Rewind Therapeutics, and Biogen and has received research funding from Biogen. D.S.R. has received research funding from Vertex Pharmaceuticals. C.L. is an advisory board member of Merck-Serono, Roche, Rewind Therapeutics, and Biogen.